This is a working overview of GHRH analog, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-08. Anything still debated is marked as such rather than presented as settled.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
== Boxed warnings == Benzhydrocodone/APAP has the potential for addiction as well as abuse and misuse, which can result in overdose and death. Serious, life-threatening, or fatal respiratory depression can occur. Accidental ingestion can cause a fatal overdose of hydrocodone. Hydrocodone can cause neonatal opioid withdrawal syndrome when taken during pregnancy. Benzhydrocodone/APAP contains acetaminophen, which can cause acute liver failure at high doses (>4000 mg a day in healthy adults). Benzhydrocodone/APAP use with CYP3A4 inhibitors can cause a fatal overdose of hydrocodone. Benzhydrocodone/APAP use with benzodiazepines or other CNS depressants can cause sedation, respiratory depression, coma or death. Benzhydrocodone is a schedule II-controlled substance. Like other opioids, benzhydrocodone has the potential to be abused. Chronic benzhydrocodone use can lead to the development of tolerance and physical dependence. Withdrawal symptoms can occur from abrupt discontinuation or rapid tapering of benzhydrocodone.
There are small amounts of 238Pu in the plutonium from usual reactors. However, isotopic separation would be quite expensive compared to another method: when 235U captures a neutron, it is converted to an excited state of 236U. Some of the excited 236U nuclei undergo fission, but some decay to the ground state of 236U by emitting gamma radiation. Further neutron capture creates 237U; which, with a half-life of 7 days, decays to 237Np. Since nearly all neptunium is produced in this way or consists of isotopes that decay quickly, one gets nearly pure 237Np. After chemical separation of neptunium, 237Np is again irradiated by reactor neutrons to be converted to 238Np, which decays to 238Pu with a half-life of 2 days.
=== Biofuels, pharmaceuticals and biomaterials === The most popular biofuel is ethanol produced from corn or sugar cane, but this method of producing biofuels is troublesome and constrained due to the high agricultural cost and inadequate fuel characteristics of ethanol. A substitute and potential source of renewable energy is microbes that have had their metabolic pathways altered to be more efficient at converting biomass into biofuels. Only if their production costs could be made to match or even beat those of present fuel production can these techniques be expected to be successful. Related to this, there are several medicines whose pricey manufacturing procedures prevent them from having a larger therapeutic range. The creation of new materials and the microbiological manufacturing of biomaterials would both benefit substantially from novel artificial biology tools.
Sources: en.wikipedia.org
=== Predicting IDPs by sequence === Separating disordered from ordered proteins is essential for disorder prediction. One of the first steps to find a factor that distinguishes IDPs from non-IDPs is to specify biases within the amino acid composition. The following hydrophilic, charged amino acids A, R, G, Q, S, P, E and K have been characterized as disorder-promoting amino acids, while order-promoting amino acids W, C, F, I, Y, V, L, and N are hydrophobic and uncharged. The remaining amino acids H, M, T and D are ambiguous, found in both ordered and unstructured regions. A more recent analysis ranked amino acids by their propensity to form disordered regions as follows (order promoting to disorder promoting): W, F, Y, I, M, L, V, N, C, T, A, G, R, D, H, Q, K, S, E, P. As it can be seen from the list, small, charged, hydrophilic residues often promote disorder, while large and hydrophobic residues promote order. This information is the basis of most sequence-based predictors. Regions with little to no secondary structure, also known as NORS (no regular secondary structure) regions, and low-complexity regions can easily be detected. However, not all disordered proteins contain such low complexity sequences.
== Further developments == Given the widespread usage of the AIDA diabetes simulation software, there has been considerable interest worldwide in updates to the program. Work has been reported in the scientific literature into the incorporation of lispro (Humalog)-like rapidly acting insulin analogues, and the glargine (Lantus) very long-acting insulin analogue, into the freeware diabetes simulator. Further information can be found in the medical / scientific literature. A beta release of AIDA [v4.5c (beta)] incorporating lispro, regular, NPH and glargine insulins is available for download from the AIDA website. AIDA v4.5c (beta) is still undergoing testing / further development but has been available without charge from the AIDA website since 2012.
== Etymology == The name Cossack (Russian: казак, romanized: kazak; Ukrainian: козак, romanized: kozak) was widely used to characterise "free people" (compare Turkic qazaq, which means "free men") as opposed to others with different standing in feudal society (i.e., peasants, nobles, clergy, etc.). The name "cossack" was also applied to migrants, free-booters and bandits. It has the same etymological root as "Kazakh", an unrelated Central Asian Turkic people.
Sources: en.wikipedia.org
Block copolymers are made up of blocks of different polymerized monomers. For example, polystyrene-b-poly(methyl methacrylate) or PS-b-PMMA (where b = block) is usually made by first polymerizing styrene, and then subsequently polymerizing methyl methacrylate (MMA) from the reactive end of the polystyrene chains. This polymer is a "diblock copolymer" because it contains two different chemical blocks. Triblocks, tetrablocks, multiblocks, etc. can also be made. Diblock copolymers are made using living polymerization techniques, such as atom transfer free radical polymerization (ATRP), reversible addition fragmentation chain transfer (RAFT), ring-opening metathesis polymerization (ROMP), and living cationic or living anionic polymerizations. An emerging technique is chain shuttling polymerization. The synthesis of block copolymers requires that both reactivity ratios are much larger than unity (r1 >> 1, r2 >> 1) under the reaction conditions, so that the terminal monomer unit of a growing chain tends to add a similar unit most of the time. The "blockiness" of a copolymer is a measure of the adjacency of comonomers vs their statistical distribution. Many or even most synthetic polymers are in fact copolymers, containing about 1-20% of a minority monomer. In such cases, blockiness is undesirable. A block index has been proposed as a quantitative measure of blockiness or deviation from random monomer composition.
After a stint of films and projects that were ambivalently received, Kidder sustained serious injuries in a car accident that left her temporarily paralyzed in 1990, and suffered from a highly publicized manic episode and nervous breakdown in 1996 stemming from bipolar disorder. Kidder thereafter maintained steady work in independent films and television, notably appearing in the hockey film Chicks with Sticks (2004) and the horror picture Halloween II (2009), and playing a guest role on R.L. Stine's The Haunting Hour (2015). She maintained dual citizenship and was an outspoken political, environmental and antiwar activist. Kidder died on May 13, 2018, of an alcohol and drug overdose, which was ruled a suicide.
FIAU can be synthesized in many ways, with one of the recent ones following a glycosylation strategy typically used in nucleoside chemistry (Figure 2). The synthesis begins with a protected 2-deoxy-2-fluoro-1,3,5-tri-O-benzoyl-D-arabinofuranose to control reactivity at the anomeric carbon. The 5-iodouracil base is converted into a silylated form. Glycosylation is promoted using trimethylsilyl trifluoromethanesulfonate (TMSOTF), which activates the sugar derivative and enables formation of the glycosidic bond between the N1 nitrogen from the pyridine base and the anomeric carbon from the sugar. This procedure simplifies earlier synthetic steps but yields a 1:1 yield of both α and β anomers. Other approaches have demonstrated improved β selectivity (Figure 3). Synthesis of closely related 2-deoxy-2-fluoro-β-D-arabinofuranosesyluracil derivatives employ pre-activated glycosyl donors (such as 1-bromo-2-fluoro sugar intermediates), which resulted in preferential formation of the β anomer in significantly higher proportions. This difference indicates that choice of glycosyl donor has a high influence on the α:β anomer ratio in FIAU, and related nucleoside analogues, synthesis. Although the mentioned strategies involve radiolabelled fluorine-18, the overall synthetic approach is applicable to normal FIAU formation since isotopic substitution does not alter the bonding or reaction pathway.
GLaDOS was built to control the facility and monitor the tests, but researchers found that the computer had villainous tendencies, threatening to kill the entire staff before it was shut down in time. The Aperture researchers constructed a number of "personality cores" that would fit onto GLaDOS to prevent her from turning against them. Despite this, on the day she was officially activated (coincidentally on "Take Your Daughter to Work Day"), she turned against the researchers and killed nearly everyone in the facility with lethal doses of neurotoxin gas. In the games and the comic Lab Rat, one employee Doug Rattmann survived due to his schizophrenia and distrust of GLaDOS. In trying to find a way to defeat GLaDOS, he finds that Chell, one of the human subjects kept in cryogenic storage within Aperture, has a high level of tenacity, and arranges for the events of Portal to occur by moving her to the top of GLaDOS' testing list. GLaDOS remains driven to test human subjects despite the lack of humans.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.